What is pathophysiology of Prostate cancer?

['ⵙⵎⴷ ⵜⴰⵖⴹⴼⵜ ⴰⴷ']

ⵎⴰⵜⵜⴰ ⵜⴰⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉⵜ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ?

ⴷⴰ ⵉⵜⵜⴰⵡⵙ ⵓⴼⵙⵉ ⴰⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ ⴳ ⵉⵎⵉⴽⴰⵏⵉⵣⵎⵏ ⴷ ⵜⵎⴳⴳⵉⵜⵉⵏ ⵜⵉⴷⵙⵍⴰⵏⵉⵏ ⵏⵏⴰ ⴷ ⵢⵓⵡⵉⵏ ⵙ ⵓⵙⴱⵓⵖⵍⵓ ⴷ ⵓⴱⵓⵖⵍⵓ ⵏ ⵜⵎⴰⴹⵓⵏⵜ.

ⵉⴳⴰ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵜⴰⵖⵢⴰⵢⵜ ⵏ ⵜⵓⵔⵉⵏ ⵢⴰⵏ ⵓⵖⵢⴰⵢ ⵉⵛⵇⵇⴰⵏ ⵉⵜⵜⴱⵓⵖⵍⵓⵏ ⵙⴳ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵜⵓⵔⵉⵏ ⵏ ⵜⵓⵔⵉⵏ, ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⴳⵎⴰⵎ ⵉⵎⵥⵥⵉⵏ, ⵉⵍⴰⵏ ⵜⴰⵍⵖⴰ ⵏ ⵡⵓⵜⵛⵉ ⵉⵍⵍⴰⵏ ⴷⴷⴰⵡ ⵏ ⵓⴱⵍⴽⵉⵎ ⵏ ⵜⵓⵥⵥⵓⵎⵜ ⴳ ⵉⵔⴳⴰⵣⵏ.

ⴷⴰ ⵜⵙⵙⵓⴼⵖ ⵜⵓⵔⵉⵏ ⵏ ⵜⴱⵔⴱⴰⵜ ⵉⴷⴰⵎⵎⵏ, ⵏⵏⴰ ⵉⵙⵎⵓⵜⵜⴳⵏ ⴰⵔ ⵉⵜⵜⵎⴰⵜⵜⴰⵢ ⵉⵔⴳⴰⵣⵏ.

ⵓⵔ ⴷⴰ ⵉⵜⵜⵓⵙⵎⵓⵙⵙⵓ ⵓⵙⵙⵏⵜⵍ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵜⴰⴳⴳⴰⵢⵜ ⵙ ⵓⵎⴰⵜⴰ, ⵎⴰⵛⴰ ⵜⵜⵓⵙⵙⴰⵏⵏ ⴽⵉⴳⴰⵏ ⵏ ⵉⵎⵙⴽⴰⵔⵏ ⵏⵏⴰ ⵉⵙⴷⵓⵙⵏ ⵜⴰⵣⵎⵔⵜ ⵏ ⵓⵙⵙⴱⵓⵖⵍⵓ ⵏ ⵜⵎⴰⴹⵓⵏⵜ.

ⵉⵍⵍⴰ ⴳⵉⵙⵏ ⵓⵣⵎⵣ, ⴰⵎⵣⵔⵓⵢ ⵏ ⵜⵡⵊⴰ, ⵜⴰⵡⵙⵉⵜ, ⴷ ⴽⵔⴰ ⵏ ⵉⵙⵏⴼⵍⵏ ⵉⵊⵉⵏⵉⵜⵏ.

ⴰⵟⵟⴰⵏ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ ⵉⴳⴰ ⵡⴰⵏⵏⴰ ⵉⴳⴳⵓⵜⵏ ⴳ ⵉⵔⴳⴰⵣⵏ ⵉⵅⴰⵜⵔⵏ, ⴷ ⵜⵓⴳⵜ ⵏ ⵡⴰⴷⴷⴰⴷⵏ ⴷⴰ ⵜⵜⵉⵍⵉⵏ ⴳ ⵉⵔⴳⴰⵣⵏ ⵉⵟⵟⴰⴼⵏ ⵓⴳⴳⴰⵔ ⵏ 65 ⵏ ⵓⵙⴳⴳⵡⴰⵙ.

ⵙ ⵓⵙⵎⵔⵙ ⵏ ⵎⴰⵢⴰ, ⴰⵔ ⵜⵜⵓⴳⵣⵏ ⵉⵎⵣⴷⴰⵖⵏ ⵉⵔⴳⴰⵣⵏ ⵉⵍⴰⵏ ⵓⵎⵣⵔⵓⵢ ⵏ ⵜⵡⵊⴰ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ ⴳ ⵉⵎⵉⵣⵉ ⵏ ⵓⵙⴱⵔⴽⵙ, ⵣⵓⵏ ⴷ ⵉⵔⴳⴰⵣⵏ ⵉⴼⵔⵉⵇⵉⵢⵏ ⴷ ⵡⵉⵏ ⵓⵎⵣⴰⵔⴰⵢ ⵏ ⴽⴰⵔⴰⵢⵉⴱ.

ⵜⴰⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉⵜ ⵏ ⵍⴽⴰⵕⵚⵓⵎ ⵏ ⵜⴰⵖⵢⴰⵢⵜ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ ⴷⴰ ⵉⵜⵜⴻⵎⵓⵏ ⴷ ⵜⴳⵎⵉ ⵓⵔ ⵉⵜⵜⵓⵃⴹⴰⵏ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⴳ ⵓⴳⵏⵙⵓ ⵏ ⵜⴰⵖⵢⴰⵢⵜ ⵏ ⵓⴱⵕⵓⵚⵟⴰⵜ.

ⵉⵖⵢ ⴰⴷ ⵢⵉⵍⵉ ⵓⵢⴰ ⵙ ⵜⵎⵏⵜⵉⵍⵜ ⵏ ⵜⵎⵓⵜⵜⵔⵜ ⵜⴰⵊⵉⵏⵉⵜ ⵏⵏⴰ ⴷ ⵢⵓⵡⵉⵏ ⵙ ⵜⴱⵔⵉⴷⵜ ⵏ ⵓⵡⵇⵇⵔ ⵏ ⵜⴱⵔⵉⴷⵜ ⵏ ⴽⵔⴰ ⵏ ⵉⵎⵙⴽⴰⵔⵏ ⵏ ⵜⵎⵔⵏⵉⵡⵜ ⵏⵖⴷ ⴰⵙⴱⴷⴷⵉ ⵏ ⵉⵊⵉⵏⵏ ⵉⵎⵙⴱⴷⴷⴰⵏ ⵏ ⵓⵖⵉⵍⵓⴼ.

ⵣⵎⵔⵏ ⵉⵙⵏⴼⵍⵏ ⴰⴷ ⴰⴷ ⴰⵡⵉⵏ ⴳ ⵜⴳⵎⵉ ⵓⵔ ⵉⵜⵜⵓⵙⵏⵎⴰⵍⴰⵏ ⵏ ⵜⵖⵔⴰⵙⵉⵏ, ⵏⵏⴰ ⵉⵜⵜⴰⵡⵉⵏ ⴳ ⵓⵙⵎⵓⵜⵜⴳ ⵏ ⵓⵖⵉⵍⵓⴼ.

ⵎⴽ ⴷⴰ ⵉⵜⵜⴱⵓⵖⵍⵓ ⵓⵖⵢⴰⵢ, ⵉⵖⵢ ⴰⴷ ⵉⴽⵛⵎ ⵙ ⵉⴳⵍⵎⴰⵎⵏ ⴷ ⵉⴳⵍⵎⴰⵎⵏ ⵉⵍⵍⴰⵏ ⵜⴰⵎⴰ ⵏⵏⵙ, ⵣⵓⵏⴷ ⴰⴱⵍⴽⵉⵎ, ⴰⵅⵅⴰⵎ, ⴷ ⵉⴳⵊⴷⴰ ⵏ ⵜⴷⵓⵙⵉ ⵉⵍⵍⴰⵏ ⵜⴰⵎⴰ ⵏⵏⵙ.

ⴳ ⴽⵔⴰ ⵏ ⵡⴰⴷⴷⴰⴷⵏ, ⵉⵖⵢ ⴰⴷ ⵉⴱⴹⵓ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵙⴳ ⵓⵖⵢⵓⵍ ⴰⵎⵣⵡⴰⵔⵓ ⴷ ⴰⴷ ⵙⵙⵉⴷⵔⵏ ⵖⵔ ⵜⴼⵓⵍⵉⵏ ⵢⴰⴹⵏⵉⵏ ⵏ ⵜⴼⴳⴳⴰ ⵙ ⵓⴱⵔⵉⴷ ⵏ ⵉⴷⴰⵎⵎⵏ ⵏⵖⴷ ⴰⵏⴳⵔⴰⵡ ⵏ ⵉⴷⴰⵎⵎⵏ, ⵢⴰⵜ ⵜⵎⴳⴳⵉⵜ ⵉⵜⵜⵡⴰⵙⵙⵏ ⵙ ⵓⴱⵔⵉⴷ ⵏ ⵜⵙⵏⴼⵙⵉⵜ.

ⵍⵍⵉⵖ ⵜⴱⴰⴷⵍ ⵜⵖⵎⵉ ⵏ ⵍⴽⵓⵏⵚⵉⵕ, ⵉⵖⵢ ⴰⴷ ⵉⴳ ⵡⴰⵏⵏⴰⵍ ⵏ ⵓⵙⵎⴽⵍ.

ⵉⵖⵢ ⴰⴷ ⵢⵉⵍⵉ ⵓⴹⴼⵓⵕ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ ⵙⴳ ⵉⵎⵙⴽⴰⵔⵏ ⵉⵀⵓⵔⵎⵓⵏⵏ, ⵙⵍⴰⵡⴰⵏ ⴰⴽⴽⵡ ⵉⵀⵓⵔⵎⵓⵏⵏ ⵉⵀⵓⵔⵎⵓⵏⵏ ⵏ ⵓⴱⵔⵓⵜⵉⵙⵜⵓⵔⵓⵏ.

ⵉⵖⵢ ⴰⴷ ⵉⵙⵎⵓⵙⵙⵓ ⵓⵜⵉⵙⵜⵓⵙⵜⵓⵔⵓⵏ ⵜⵉⴳⵎⵉ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵜⴱⵕⵓⵚⵟⴰⵜ, ⴷ ⴽⵉⴳⴰⵏ ⵏ ⵜⴱⵔⵉⴷⵉⵏ ⵏ ⵓⵙⵓⵊⵊⵉ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵜⴱⵕⵓⵚⵟⴰⵜ ⴰⵔ ⵜⵜⴰⴳⴳⴰ ⵅⴼ ⵓⵙⴷⵔⴼⵉ ⵏ ⵉⵙⵡⵉⵔⵏ ⵏ ⵓⵀⵓⵔⵎⵓⵏ ⴰⴷ ⵏⵖⴷ ⴰⵙⴱⴷⴷⵉ ⵏ ⵜⵢⴰⴼⵓⵜⵉⵏ ⵏⵏⵙ.

ⵙ ⵓⵙⵙⴳⵎⴹ, ⵜⴰⴱⴰⵜⵓⴼⵉⵣⵉⵢⵓⵍⵓⵊⵉⵜ ⵏ ⵍⴽⵓⵏⵚⵉⵕ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ ⴷⴰ ⵉⵜⵜⴰⵡⵙ ⴳ ⵜⵎⵔⵏⵉⵡⵜ ⵓⵔ ⵉⵜⵜⵓⵃⴹⴰⵏ ⴷ ⵓⴱⵟⵟⵓ ⵏ ⵜⵖⵔⴰⵙⵉⵏ ⴳ ⵓⴳⵏⵙⵓ ⵏ ⵜⵓⵔⵉⵏ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ, ⵏⵏⴰ ⵉⵖⵉⵏ ⴰⴷ ⵢⵉⵍⵉ ⴳ ⵓⵙⵏⴼⵍ ⵏⵏⵙ ⵙⴳ ⵉⵎⴳⴳⵉⵜⵏ ⵉⵊⵉⵏⵉⵜⵏ ⴷ ⵉⵀⵓⵔⵎⵓⵏⵏ ⴷ ⵜⵡⵏⵏⴰⴹⵜ.

ⵉⴳⴰ ⵓⵔⵎⴰⵙ ⵏ ⵉⵎⵉⴽⴰⵏⵉⵣⵎⵏ ⵏ ⵜⵊⵊⵉⵜ ⵏ ⵜⵎⴰⴹⵓⵏⵜ ⴰⴷ ⴰⵙⵏⵡⴰⵏ ⵉ ⵓⵙⴱⵓⵖⵍⵓ ⵏ ⵜⵊⵊⵉⵜⵉⵏ ⵉⵕⵡⴰⵏ ⴷ ⵓⵙⵖⵓⴷⵓ ⵏ ⵜⵢⴰⴼⵓⵜⵉⵏ ⵉ ⵢⵉⵎⵓⴹⵉⵏⵏ ⵍⵍⵉ ⴷⴰⵔ ⵍⵍⴰⵏⵜ ⵜⵓⵔⵉⵏ ⵏ ⵍⴱⵕⵓⵚⵟⴰⵜ.

['ⵉⵙⵓⴳⴰⵎ']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Zobniw CM, Causebrook A, Fong MK: Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. Res Rep Urol. 2014, 6 (): 97-105.

Lim HY, Agarwal AM, Agarwal N, Ward JH: Recurrent epistaxis as a presenting sign of androgen-sensitive metastatic prostate cancer. Singapore Med J. 2009, 50 (5): e178-80.

Kohli M, Qin R, Jimenez R, Dehm SM: Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer. Adv Urol. 2012, 2012 (): 781459.

Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995, 1 (9): 944-9.

Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M: Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs. 2013, 22 (11): 1385-400.

Kotani K, Sekine Y, Ishikawa S, Ikpot IZ, Suzuki K, Remaley AT: High-density lipoprotein and prostate cancer: an overview. J Epidemiol. 2013, 23 (5): 313-9.

Jadvar H: Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging. , 8 (2): 56-64.

['ⴰⵙⴱⴷⵉⴷ: ⴰⵎⵙⵏⵉⵊⵊⵉ']

['ⴰⵙⵉⵜ ⴰⴷ, ⴷⴰ ⵉⵜⵜⵓⴼⴽⴰ ⵖⴰⵙ ⵉ ⵜⵖⴰⵡⵙⵉⵡⵉⵏ ⵏ ⵓⵙⴳⵎⵉ ⴷ ⵉⵏⵖⵎⵉⵙⵏ, ⵓⵔ ⵉⴳⵉ ⴰⵖⴰⵡⴰⵙ ⵏ ⵜⵉⴽⴽⵉ ⵏ ⵜⵉⵏⵓⵔⵣⵉⵜⵉⵏ ⵜⵉⴷⵓⵙⴰⵏⵉⵏ ⵏⵖⴷ ⵜⵉⵡⵓⵔⵉⵡⵉⵏ ⵜⵉⵣⵣⵓⵍⴰⵏⵉⵏ.']

['ⵓⵔ ⵉⵅⵚⵚⴰ ⴰⴷ ⵜⵜⵓⵙⵎⵔⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵎⵔⵙ ⵏ ⵓⵙⵎⵉⴳⵍ ⵏⵉⵖ ⵉⵊⵉⵊⵊⵉ ⵏ ⵉⵎⵓⴽⵔⵉⵙⵏ ⵏ ⵜⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵎⴰⴹⵓⵏⵉⵏ, ⴷ ⵡⵉⵏⵏⴰ ⵉⵔⴰⵏ ⴰⵙⵖⵏⵓ ⴰⵎⵙⵏⵉⵊⵊⵉ ⴰⵡⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⵉⵇⵇⴰⵏ ⴰⴷ ⵉⵙⴰⵡⵍ ⴷ ⵢⴰⵏ ⵓⵎⵙⵏⵉⵊⵊⵉ ⵉⵜⵜⵓⵊⵊⴰⵏ.']

['ⵙⵙⴽⵜⵉ ⴳ ⵜⴱⵔⴰⵜ ⵎⴰⵙ ⵜⵣⵟⵟⴰ ⵏ ⵜⵎⴰⵖⵓⵏⵜ ⵏⵏⴰ ⵉⵜⵜⴰⵔⴰⵏ ⵜⵉⵎⵔⴰⵔⵓⵜⵉⵏ ⵉ ⵉⵙⵇⵙⵉⵜⵏ, ⵓⵔ ⵜⴽⴽⵉ ⵜⵖⴰⵔⴰ ⴽⵉⴳⴰⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵜⵓⵎⴰⵢⵜ ⵏ ⵓⵟⵟⵓⵏ. ⵙ ⵓⵎⴷⵢⴰ, ⵓⵟⵟⵓⵏ ⵏ ⵎⴷⴷⵏ ⵉⵜⵜⵓⵙⵏⴼⴰⵍⵏ ⵉ ⵜⵎⴰⴹⵓⵏⵜ ⵉⵥⵍⵉⵏ.']

['ⴰⵀⴰ ⵣⵣⵔⵉⵢ ⵉ ⵓⵎⵙⴰⵙⴰ ⵏ ⵓⴷⵓⴽⵜⵓⵕ ⵏⵏⴽ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⵙⵙⵉⵡⵍ ⵏ ⵜⴷⵓⵙⵉ ⵢⴰⴹⵏ ⵉⵖⵉⵢⵏ ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵓⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵏⵏⴽ. ⵓⵔ ⴰⴽⴽⵡ ⵜⵃⵍⴰⵎ ⴰⵖ ⴰⵖⴰⵎⵓⵙ ⵏ ⵓⴷⵓⵙⵉ ⵏⵖⴷ ⵜⵉⵖⵣⵉ ⴳ ⵓⵙⵣⵣⵔⵉⵢ ⵏⵏⵙ ⴰⵛⴽⵓ ⵏⵜⵜⴰⵜ ⵜⵖⵔⵉⴷ ⴳ ⵓⵙⵉⵜ ⴰⴷ. ⵎⴽ ⵜⵓⵔⴷⴰ ⵎⴰⵙ ⴷⴰⵔⴽ ⴰⴷ ⵢⵉⵍⵉ ⵢⴰⵏ ⵓⴷⴷⴰⴷ ⵏ ⵜⴷⵓⵙⵉ ⵉⵣⵉⵍⵏ, ⵙⴰⵡⵍⴰⵜ ⵙ 911 ⵏⵖⴷ ⴷⴷⵓ ⵙ ⵓⵙⵉⵔⴰ ⵏ ⵓⵣⵣⵔⴰⵢ ⵏ ⵣⵉⴽⴽ. ⵓⵔ ⴷⴰ ⵉⵜⵜⵓⵙⴽⴰⵔ ⴽⵔⴰ ⵏ ⵓⵣⴷⴰⵢ ⵏ ⵓⵎⵙⴳⵏⴰⴼ ⴷ ⵓⵎⵏⵉⴳ ⵙ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⴰⵙⵎⵔⵙ ⵏⵏⵙ. ⵓⵔ ⴷⴰ ⵜⵙⴽⴰⵔ ⴱⵢⵓⵎⵉⴷⵍⴱ ⵏⵖⴷ ⵉⵎⵙⵡⵓⵔⵉⵏ ⵏⵏⵙ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵎⴷⵔⴰⵡ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⴽⵔⴰ ⵏ ⵓⵙⵎⵏⵉⴷ, ⵙ ⵡⴰⵡⴰⵍ ⵏⵖⴷ ⵙ ⵓⵙⵓⵎⵔ, ⴳ ⵎⴰⴷ ⵉⵥⵍⵉⵏ ⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⵉⵜ ⴰⴷ ⵏⵖⴷ ⵓⵙⵎⵔⵙ ⵏⵏⵙ.']

['ⵉⵣⵍⵉ: ⵉⵣⵔⴼⴰⵏ ⵏ ⵜⵉⵔⵔⴰ']

['ⵉⵍⵍⴰ ⴳ ⵓⵙⵍⴳⵏ ⵏ ⵓⵣⵔⴼ ⴰⵎⵓⵟⵟⵓⵏ ⵏ ⵓⵙⵏⴼⵍ ⵏ ⵜⵏⵖⵎⴰⵙⵜ ⵏ ⵓⵙⴳⴳⵡⴰⵙ ⵏ 1998, 17 U.S.C. § 512 (DMCA) ⵜⴰⵙⵏⵜⴰⵢⵜ ⵉ ⵉⵎⵥⵢⴰⵏⵏ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵜⵏⵖⵎⴰⵙⵜ ⵏⵏⴰ ⵙⵙⵉⵜⵉⵎⵏ ⵉⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵏⵏⴰ ⴷ ⵉⵜⵜⴼⴼⵖⵏ ⴳ ⵡⴰⵏⵜⵉⵔⵏⵉⵜ ⴷⴰ ⵜⵜⴳⴳⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏⵏⵙⵏ ⴷⴷⴰⵡ ⵓⵣⵔⴼ ⴰⵎⵓⵟⵟⵓⵏ ⴰⵎⵉⵔⵉⴽⴰⵏⵉ. ']

['ⵎⴽ ⵜⵍⵍⵉⴷ ⵙ ⵜⵖⴰⵍⵜ ⵉⵖⵓⴷⴰⵏ ⵎⴰⵙⴷ ⴽⵔⴰ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⴽⵔⴰ ⵏ ⵓⵙⵏⴼⴰⵔ ⵉⵜⵜⵓⴼⴽⴰⵏ ⴳ ⵓⵙⴷⴰⵡ ⵏⵏⵓⵏ ⵏⵖⴷ ⵜⵉⵙⵏⵙⵉ ⵏⵏⵓⵏ ⴷⴰ ⵉⵙⵙⴽⴰⵔ ⵜⵉⵕⵥⵉ ⵏ ⵓⵣⵔⴼ ⵏⵏⵓⵏ ⵏ ⵜⵉⵔⵔⴰ, ⵉⵖⵢ ⴰⴷ ⵜⴰⴷ ⴼⵍⵍⴰⵙ ⵏⵙⵔⵖⴷ (ⵏⵖⴷ ⴰⵎⴷⵢⴰⵣ ⵏⵏⴽ) ⵢⴰⵏ ⵓⵙⵏⵖⵎⵙ ⵏ ⵓⵙⵓⵜⵔ ⵏ ⵓⵙⵏⴼⴰⵔ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵖⴷ ⴰⵙⵏⴼⴰⵔ ⴰⴷ ⵏⵖⴷ ⴰⵙⴱⴷⴷⵉ ⵏ ⵓⵣⵔⴼ ⵏ ⵓⴽⵛⵛⵓⵎ ⵖⵔⵙⵏ. ']

['ⵉⵇⵇⴰⵏ ⴰⴷ ⵜⵜⵢⵓⵔⴰⵢ ⵜⴱⵔⴰⵜ ⴰⴷ ⵙ ⵜⵖⴰⵔⴰⵙⵜ ⵏ ⵜⵉⵔⵔⴰ ⵙ ⵜⴱⵔⴰⵜ ⵜⵉⵍⵉⴽⵜⵕⵓⵏⵉⵜ (ⵥⵕ ⴰⵙⴷⴰⵡ ⵏ ⵜⴱⵔⴰⵜ ⵜⵉⵍⵉⴽⵜⵕⵓⵏⵉⵜ ⴳ ⵓⵎⵏⵏⵉ "ⵉⵎⵢⴰⵡⴰⴹⵏ").']

['ⴷⴰ ⵉⵜⵜⴻⵖⵜⴰⵙ ⵓⵙⵍⴳⵏ ⵏ ⵓⵎⵏⵖⵉ ⵅⴼ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵉⵙ ⴷ ⵉⵇⵇⴰⵏ ⴰⴷ ⴳⵉⵙ ⵉⵍⵉⵏ ⵉⵏⵖⵎⵉⵙⵏ ⴰⴷ: (1) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵡⵓⵔⵉ ⵉⵍⴰⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵜⵍ ⵏ ⵓⵣⵔⴼ ⵏ ⵓⵎⴳⴰⵢ; (2) ⴰⵙⵏⵓⵎⵍ ⵏ ⵜⵓⵎⴰⵢⵜ ⵏⵏⴰ ⵉⴳⴰⵏ ⴰⵙⵏⵓⵎⵍ ⵏ ⵉⵣⵔⴼⴰⵏ ⴷ ⵉⵏⵖⵎⵉⵙⵏ ⵏⵏⴰ ⵢⵓⵙⴰⵏ ⵃⵎⴰ ⴰⴷ ⵜ ⵏⴰⴼ; (3) ⵉⵏⵖⵎⵉⵙⵏ ⵏ ⵓⵎⵢⴰⵡⴰⴹ ⴰⴽⴷⴽ, ⴳ ⵉⵍⵍⴰ ⵓⵙⵖⵉⵎ ⵏⵏⴽ ⴷ ⵓⵟⵟⵓⵏ ⵏ ⵜⵉⵍⵉⴼⵓⵏ ⴷ ⵓⴷⵖⴰⵔ ⵏ ⵍⵢⵉⴱⵍ; (4) ⴰⵙⵉⵡⴹ ⵏⵏⴽ ⵏ ⵓⵙⵏⵓⵎⵍ ⵉⵖⵓⴷⴰⵏ ⵏⵏⴰ ⴳ ⵜⵍⵍⴰ ⵜⵣⵎⵎⴰⵔ ⵏ ⵓⵙⵏⵓⵎⵍ ⵏ ⵓⵙⵏⴼⵍ ⵏⵏⴰ ⵙ ⵉⵜⵜⵓⵙⵎⴳⴰⵍ ⵓⵔ ⵜ ⵢⵓⵊⵊⵉ ⵓⵎⵏⴳⴰⵢ ⵏ ⵉⵣⵔⴼⴰⵏ ⵏ ⵓⵎⴳⴰⵢ, ⵏⵖⴷ ⵓⵎⴷⵢⴰⵣ ⵏⵏⵙ, ⵏⵖⴷ ⵙ ⵓⴹⴼⴰⵕ ⵏ ⴽⵔⴰ ⵏ ⵓⵙⵍⴳⵏ; ']

['5. ⵢⴰⵏ ⵓⵙⵉⵡⴹ ⵏⵏⴽ, ⵉⵜⵜⵓⵙⴳⵎⴰⴹⵏ ⴷⴷⵓ ⵏ ⵓⵃⵟⵟⵓ ⵏ ⵜⵔⴳⴰⵍⵜ, ⵎⴰⵙ ⵉⵏⵖⵎⵉⵙⵏ ⵉⵍⵍⴰⵏ ⴳ ⵓⵏⵖⵎⵉⵙ ⴰⴷ ⴳⴰⵏ ⵉⵙⴷⴰⵡⵏ ⴷ ⵎⴰⵙ ⵖⵓⵔⴽ ⵜⵓⵔⴰⴳⵜ ⴰⴼⴰⴷ ⴰⴷ ⵜⵙⵎⴷⵔⴼ ⵜⵉⵡⵏⴳⵉⵎⵉⵏ ⵉⵜⵜⵉⵏⵉ ⵉⵙ ⵜⵜⵓⵙⵏⴼⴰⵍⵏ;']

['ⴷ (6) ⵢⴰⵏ ⵓⵣⵎⵎⴻⵎ ⴰⴽⵎⴰⵎ ⵏⵖⴷ ⴰⵍⵉⴽⵜⵔⵓⵏⵉ ⵏ ⵉⵎⵥⵍⵉ ⵏ ⵓⵣⵔⴼ ⵏ ⵜⵉⵔⵔⴰ ⵏⵖⴷ ⵢⴰⵏ ⵓⴼⴳⴰⵏ ⵉⵜⵜⵓⵙⵎⴰⴳⵍⵏ ⵙ ⵜⵡⵓⵔⵉ ⴳ ⵜⵙⴳⴰ ⵏ ⵉⵎⵥⵍⵉ ⵏ ⵓⵣⵔⴼ ⵏ ⵜⵉⵔⵔⴰ. ']

['ⵎⴽ ⵓⵔ ⵜⵙⵎⵓⵜⵜⵉⴷ ⴽⵓⵍⵍⵓ ⵉⵏⵖⵎⵉⵙⵏ ⴰⴼⵍⵍⴰ, ⵉⵥⴹⴰⵕ ⴰⴷ ⵉⵙⵙⵉⵍⵉ ⵓⵙⵙⵉⵖⵣⵉⵏ ⵏ ⵓⵙⵎⴽⵍ ⵏ ⵡⴰⵙⵉⴼ ⵏⵏⴽ.']

['ⴰⵎⵢⴰⵡⴰⴹ']

['ⵙⵇⵙⴰⵖ ⴷⵉⵖ ⴰⴷ ⵜⵙⵏⵖⵎⵙⴷ ⴽⵔⴰ ⵏ ⵓⵙⵇⵙⵉ/ ⵜⴰⵏⵏⴰⵢⵜ.']

What is pathophysiology of prostate cancer?

The pathophysiology of prostate cancer refers to the underlying mechanisms and processes that lead to the development and progression of the disease.

Prostate cancer is a malignant tumor that arises from the cells of the prostate gland, which is a small, walnut-shaped organ located below the bladder in men.

The prostate gland produces seminal fluid, which nourishes and transports sperm.

The exact cause of prostate cancer is not fully understood, but several factors are known to increase the risk of developing the disease.

These include age, family history, race, and certain genetic mutations.

Prostate cancer is more common in older men, with the majority of cases occurring in men over the age of 65.

Additionally, men with a family history of prostate cancer are at an increased risk, as are African American men and men of Caribbean descent.

The pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland.

This can occur due to genetic mutations that lead to the overexpression of certain growth factors or the inactivation of tumor suppressor genes.

These mutations can result in the unregulated growth of cells, leading to the formation of a tumor.

As the tumor grows, it can invade nearby tissues and organs, such as the bladder, rectum, and nearby lymph nodes.

In some cases, cancer cells can break away from the primary tumor and spread to other parts of the body through the bloodstream or lymphatic system, a process known as metastasis.

Once the cancer has spread, it can be more difficult to treat.

Prostate cancer can also be influenced by hormonal factors, particularly the androgen hormone testosterone.

Testosterone can stimulate the growth of prostate cancer cells, and many treatments for prostate cancer aim to reduce the levels of this hormone or block its effects.

In summary, the pathophysiology of prostate cancer involves the uncontrolled growth and division of cells within the prostate gland, which can be influenced by genetic, hormonal, and environmental factors.

Understanding the underlying mechanisms of the disease is crucial for developing effective treatments and improving outcomes for patients with prostate cancer.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.

['ⵖⴼ']

['ⴷⴰ ⵉⵙⵙⵎⵔⴰⵙ ⴱⵢⵓⵎⵉⴷⵍⴱ ⵉⵎⴰⵙⵙⵏ ⵏ ⵓⵙⵖⵉⵡⵙ ⵉⵙⵎⵎⴰⵏⵏ (ⴰⵍⴳⵓⵔⵉⵜⵎ ⵏ ⵓⵍⵎⵎⵓⴷ ⵏ ⵉⵎⵉⵙⵏ) ⵉ ⵓⵙⵓⴼⵖ ⵏ ⵉⴽⵔⵡⴰⵏ ⵏ ⵉⵙⵇⵙⵉⵜⵏ ⴷ ⵜⵎⵔⴰⵔⵓⵜⵉⵏ.']

['ⴷⴰ ⵏⵙⵙⵏⵜⵉ ⵙ 35 ⵎⵍⵢⵓⵏ ⵏ ⵜⵥⵕⵉⴳⵉⵏ ⵜⵉⵎⵙⵏⵉⵊⵊⵉⵏ ⵏ ⵜⵓⴷⵔⵜ ⵏ ⴱⵓⴱⵎⵉⴷ/ⵎⵉⴷⵍⵉⵏ. ⴰⵡⴷ ⵜⵉⴼⵔⵜ ⵏ ⵡⵉⴱ ⵏ ⵔⵉⴼⵉⵏⴷⵡⵉⴱ.']

['ⵥⵕ "ⵜⵓⵎⴰⵔ" ⴰⵡⴷ "ⴰⵙⵎⵉⴳⵍ".']